Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonmyeloablative transplantation for lymphoma.

Sonali M Smith1

  • 1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, 5841 South Maryland Avenue MC2115, Chicago, IL 60637, USA. smsmith@medicine.bsd.uchicago.edu

Current Treatment Options in Oncology
|August 29, 2003
PubMed
Summary

Nonmyeloablative stem cell transplantation offers a novel approach to lymphoma treatment by harnessing graft-versus-lymphoma effects while reducing toxicity. This method allows donor and host cell coexistence, potentially broadening allogeneic transplantation for lymphomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Blood neoplasia·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

JAMA oncology·2026
Same author

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same author

Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.

Blood advances·2025

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Nonmyeloablative stem cell transplantation (NST) is a reduced-intensity approach for lymphoma treatment.
  • It aims to leverage graft-versus-lymphoma (GVL) effects while minimizing regimen-related toxicity.
  • The core principle involves achieving donor-host hematopoietic chimerism through immunosuppressive and moderately myelosuppressive regimens.

Purpose of the Study:

  • To evaluate the efficacy and safety of nonmyeloablative stem cell transplantation in lymphoma treatment.
  • To explore the potential of NST in harnessing GVL effects.
  • To identify optimal patient selection, preparative regimens, and GVHD prophylaxis for NST.

Main Methods:

  • Regimens commonly include purine analogs (e.g., fludarabine) combined with alkylating agents (e.g., cyclophosphamide, melphalan).

Related Experiment Videos

  • Newer regimens incorporate alemtuzumab to potentially reduce acute graft-versus-host disease (GVHD).
  • Engraftment, GVL effect, lymphoma control, and GVHD incidence are key evaluation parameters.

    • Main Results:

    • Early reports indicate a GVL effect, though its benefit is influenced by lymphoma subtype and disease pace.
    • Clinical outcomes show mixed results, likely due to variations in patient selection.
    • While most patients achieve engraftment, careful evaluation of lymphoma control and GVHD is crucial.

    Conclusions:

    • NST may expand the use of allogeneic transplantation in malignant lymphomas, particularly indolent subtypes.
    • Supportive care is vital due to persistent risks of serious infection and chronic GVHD.
    • Further research is needed to optimize NST protocols, patient selection, and GVHD management.